Matthew Burgess
Overview
Explore the profile of Matthew Burgess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larson D, Carlsson A, Valdera F, Burgess M, Leatherman L, Shaffer L, et al.
Mil Med
. 2023 Sep;
189(7-8):1505-1513.
PMID: 37776542
Introduction: Immediate evacuation of burn casualties can be challenging in austere environments, and it is predicted to be even more difficult in future multi-domain battlespaces against near-peer foes. Therefore, a...
2.
Burgess M, Valdera F, Varon D, Kankuri E, Nuutila K
Cells
. 2022 Oct;
11(19).
PMID: 36231034
Burn are diverse and complex injuries that not only have local effects but also serious systemic consequences through severe and prolonged inflammatory response. They are caused by heat, electricity, friction,...
3.
Hudson I, Staudt A, Burgess M, Hinojosa-Laborde C, Schauer S, Newberry R, et al.
Mil Med
. 2022 Sep;
188(1-2):108-116.
PMID: 36099060
Introduction: Battlefield pain management changed markedly during the first 20 years of the Global War on Terror. Morphine, long the mainstay of combat analgesia, diminished in favor of fentanyl and...
4.
Gaughan E, Quinn T, Mills A, Bruce A, Antonelli J, MacKinnon A, et al.
Am J Respir Crit Care Med
. 2022 Aug;
207(2):138-149.
PMID: 35972987
High circulating galectin-3 is associated with poor outcomes in patients with coronavirus disease (COVID-19). We hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would...
5.
Robinson A, Burgess M, Webb S, Louwe P, Ouyang Z, Skola D, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159100
There is a growing body of evidence that cancer causes systemic changes. These influences are most evident in the bone marrow and the blood, particularly in the myeloid compartment. Here,...
6.
Quinn T, Gaughan E, Bruce A, Antonelli J, OConnor R, Li F, et al.
EBioMedicine
. 2022 Feb;
76:103856.
PMID: 35152152
Background: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate. Methods:...
7.
Mitsadali I, Grayson B, Idris N, Watson L, Burgess M, Neill J
J Psychopharmacol
. 2020 May;
34(7):695-708.
PMID: 32431225
Introduction And Objectives: Cognitive impairment associated with schizophrenia (CIAS) greatly reduces patients' functionality, and remains an unmet clinical need. The sub-chronic phencyclidine (scPCP) rat model is commonly employed in studying...
8.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt A, Nemsadze G, et al.
J Clin Oncol
. 2019 Dec;
38(5):423-433.
PMID: 31841354
Purpose: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has...
9.
Burgess M, Wicks K, Gardasevic M, Mace K
Immunohorizons
. 2019 Jul;
3(7):262-273.
PMID: 31356156
Bone marrow (BM)-derived classical monocytes are critical to wound repair, where they differentiate into macrophages and purge foreign materials and dead cells while also laying the framework for tissue repair...
10.
Martyn M, Kanga-Parabia A, Lynch E, James P, Macciocca I, Trainer A, et al.
J Genet Couns
. 2019 Feb;
28(2):388-397.
PMID: 30776170
Internationally, the practice of offering additional findings (AFs) when undertaking a clinically indicated genomic test differs. In the USA, the recommendation is to include analysis for AFs alongside diagnostic analysis,...